Full-Time

Staff Mechanical Design Engineer

MP Systems

Updated on 6/24/2026

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Four days on-site per week in Sunnyvale; occasional travel to supplier/manufacturing sites.

Category
Mechanical Engineering (2)
,
Required Skills
CAD
GD&T
SolidWorks
FEM/FEA
Requirements
  • Minimum of 12 years of experience with a Bachelor’s degree, 10 years with a Masters or PhD.
  • Strong foundation in mechanical design and analysis, including tolerance stack-ups, geometric dimensioning and tolerancing, finite element analysis, materials selection, and design for manufacturability and assembly, with demonstrated ability to apply these principles to deliver robust, production-ready designs.
  • Proficient with CAD, simulation, and product lifecycle management tools such as SolidWorks, ANSYS, Windchill.
  • Demonstrated ability to lead root cause investigations.
  • Effective communicator with experience influencing technical and business decisions through cross-functional presentations.
  • Demonstrated experience mentoring junior engineers and collaboration across various functions.
  • Candidates with strong mechanical fundamentals and a genuine interest in Intuitive’s mission and values are encouraged to apply—especially those eager to grow within the medical device industry and thrive in a purpose-driven, collaborative culture.
Responsibilities
  • Work in or lead cross-functional project teams to design, develop and verify modifications to robotic or other complex mechanisms.
  • Lead mechanical design of components and subsystems for da Vinci systems, with emphasis on new enhancements, electromechanical integration, thermal design.
  • Lead root cause investigations using structured problem-solving methods (e.g., 8D, DMAIC); support CAPA activities per quality system procedures.
  • Drive cross-functional decision-making aligned with program goals, collaborating with Engineering, Clinical, Human Factors, Industrial Design, Manufacturing, Sourcing, Quality, and Regulatory.
  • Partner with suppliers and Supplier Engineers to assess capabilities, resolve process issues, and ensure parts meet design specifications.
  • Mentor junior engineers in mechanical design principles, structured problem-solving techniques, and documentation best practices to support team development.
  • Identify and implement best practices between teams and engineering departments
  • Generate and maintain design control documentation.
  • Deliver impactful technical presentations to staff, leadership, and cross-functional teams, articulating trade-offs and design rationale.
  • Contribute to risk management activities through structured risk analysis, mitigation planning, and reliability assessments using FMEA and other methods.
Desired Qualifications
  • Experience in regulated industries (e.g., medical devices, aerospace, automotive) with working knowledge of standards and documentation frameworks such as ISO 13485, FDA Quality System Regulation, IEC 60601, ISO 14971, ASTM standards, Design History File, Failure Modes and Effects Analysis, and Verification and Validation protocols.
  • Experience integrating electrical and mechanical subassemblies into complex systems (thermal, structural, wiring, printed circuit assemblies, etc.).
  • Experience with requirements architecture and interface controls in electromechanical systems.
  • Experience supporting post-market performance through reliability engineering, serviceability design, or field failure analysis.
  • Comfortable with all phases of the product development lifecycle including design, analysis, debugging, verification, transfer to manufacturing, and sustainment.
  • Strong track record of leading departmental and cross-functional projects and strategic initiatives from concept through completion.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Your Connections

People at Intuitive Surgical who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • da Vinci 5 updates create software-driven upgrades and workflow monetization.
  • Ion growth expands a second engine beyond soft-tissue robotic surgery.
  • Installed base above 11,000 systems supports durable consumables and service growth.

What critics are saying

  • FDA recalls on da Vinci instruments threaten recurring revenue and surgeon trust.
  • Lower-cost robotic rivals pressure placements, pricing, and hospital contract renewals.
  • MedTech valuation compression can outpace Intuitive's earnings growth for months.

What makes Intuitive Surgical unique

  • Pioneer of robotic-assisted surgery, anchored by da Vinci and Ion platforms.
  • Global leader in minimally invasive care, serving hospitals and surgical centers.
  • Large recurring revenue base from instruments, accessories, and service contracts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.